No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt

被引:26
|
作者
Riggio, Oliviero [1 ,2 ]
Nardelli, Silvia [1 ]
Pasquale, Chiara [1 ]
Pentassuglio, Ilaria [1 ]
Gioia, Stefania [1 ]
Onori, Eugenia [1 ]
Frieri, Camilla [1 ]
Salvatori, Filippo Maria [1 ]
Merli, Manuela [1 ]
机构
[1] Sapienza Univ Rome, Dept Clin Med, Ctr Diag & Treatment Portal Hypertens, Rome, Italy
[2] Sapienza Univ Roma, Dipartimento Med Clin, Ctr Riferimento Ipertens Portale, Gastroenterol 2, Viale Univ 37, I-00185 Rome, Italy
关键词
TIPS; Hepatic encephalopathy; Liver cirrhosis; Albumin; PARACENTESIS PLUS ALBUMIN; COVERED STENT GRAFTS; RISK-FACTORS; REFRACTORY ASCITES; VARICEAL HEMORRHAGE; RANDOMIZED-TRIAL; CIRRHOSIS; PLACEMENT; MORTALITY; VARIABLES;
D O I
10.1007/s11011-015-9713-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hepatic encephalopathy (HE) is a major problem in patients submitted to TIPS. Previous studies identified low albumin as a factor associated to post-TIPS HE. In cirrhotics with diuretic-induced HE and hypovolemia, albumin infusion reduced plasma ammonia and improved HE. Our aim was to evaluate if the incidence of overt HE (grade II or more according to WH) and the modifications of venous blood ammonia and psychometric tests during the first month after TIPS can be prevented by albumin infusion. Twenty-three patients consecutively submitted to TIPS were enrolled and treated with 1 g/Kg BW of albumin for the first 2 days after TIPS followed by 0,5 g/Kg BW at day 4th and 7th and then once a week for 3 weeks. Forty-five patients included in a previous RCT (Riggio et al. 2010) followed with the same protocol and submitted to no pharmacological treatment for the prevention of HE, were used as historical controls. No differences in the incidence of overt HE were observed between the group of patients treated with albumin and historical controls during the first month (34 vs 31 %) or during the follow-up (39 vs 48 %). Two patients in the albumin group and three in historical controls needed the reduction of the stent diameter for persistent HE. Venous blood ammonia levels and psychometric tests were also similarly modified in the two groups. Survival was also similar. Albumin infusion has not a role in the prevention of post-TIPS HE.
引用
收藏
页码:1275 / 1281
页数:7
相关论文
共 50 条
  • [21] Application of fecal microbial transplantation in hepatic encephalopathy after transjugular intrahepatic portosystemic shunt
    Li, Jun
    Wang, Dan
    Sun, Jingping
    MEDICINE, 2022, 101 (03)
  • [22] The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt A Randomized Controlled Trial
    Bureau, Christophe
    Thabut, Dominique
    Jezequel, Caroline
    Archambeaud, Isabelle
    D'Alteroche, Louis
    Dharancy, Sebastien
    Borentain, Patrick
    Oberti, Frederic
    Plessier, Aurelie
    De Ledinghen, Victor
    Ganne-Carrie, Nathalie
    Carbonell, Nicolas
    Rousseau, Vanessa
    Sommet, Agnes
    Peron, Jean Marie
    Vinel, Jean Pierre
    ANNALS OF INTERNAL MEDICINE, 2021, 174 (05) : 633 - +
  • [23] Hepatic encephalopathy and survival after transjugular intrahepatic portosystemic shunt: Do spontaneous portosystemic shunts matter?
    Zhang, Feng
    Zhang, Ming
    Wang, Lei
    Zhuge, Yuzheng
    JOURNAL OF HEPATOLOGY, 2024, 80 (06) : e260 - e261
  • [24] Effects of different stent configurations on shunt failure and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt
    李伟之
    ChinaMedicalAbstracts(InternalMedicine), 2018, 35 (01) : 42 - 43
  • [25] Combined Spontaneous Portosystemic Shunt Embolization and Transjugular Intrahepatic Portosystemic Shunt Creation for Treatment of Hepatic Encephalopathy
    Gurtatta, Rajangad S.
    Gaba, Ron C.
    Herren, Josi L.
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2024, 35 (05) : 659 - 663
  • [26] Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study
    Riggio, O
    Masini, A
    Efrati, C
    Nicolao, F
    Angeloni, S
    Salvatori, FM
    Bezzi, M
    Attili, AF
    Merli, M
    JOURNAL OF HEPATOLOGY, 2005, 42 (05) : 674 - 679
  • [27] A nomogram to predict the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in Cirrhotic Patients
    Xiaochun Yin
    Feng Zhang
    Huiwen Guo
    Chunyan Peng
    Wei Zhang
    Jiangqiang Xiao
    Yi Wang
    Xiaoping Zou
    Ming Zhang
    Yuzheng Zhuge
    Scientific Reports, 10
  • [28] Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study
    Yang Yang
    Sirui Fu
    Bin Cao
    Kenan Hao
    Yong Li
    Jianwen Huang
    Wenfeng Shi
    Chongyang Duan
    Xiao Bai
    Kai Tang
    Shirui Yang
    Xiaofeng He
    Ligong Lu
    Hepatology International, 2021, 15 : 730 - 740
  • [29] Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study
    Yang, Yang
    Fu, Sirui
    Cao, Bin
    Hao, Kenan
    Li, Yong
    Huang, Jianwen
    Shi, Wenfeng
    Duan, Chongyang
    Bai, Xiao
    Tang, Kai
    Yang, Shirui
    He, Xiaofeng
    Lu, Ligong
    HEPATOLOGY INTERNATIONAL, 2021, 15 (03) : 730 - 740
  • [30] Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement
    Nardelli, Silvia
    Lattanzi, Barbara
    Torrisi, Sabrina
    Greco, Francesca
    Farcomeni, Alessio
    Gioia, Stefania
    Merli, Manuela
    Riggio, Oliviero
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (06) : 934 - 936